Last week, the Ministry of Innovative Development of Uzbekistan and the Chinese company BGI, specializing in clinical diagnostics and genetics, signed a Memorandum of Understanding aimed at introducing the methods of early diagnosis of genetic disorders in newborns, children and adults and family planning methods in Uzbekistan, the press office of the Ministry reported.
The opening ceremony of the Genscreen joint venture with BGI Genomics – the BGI’s clinical division took place. Genscreen will conduct neonatal screening tests for orphan (rare) diseases and genetic tests for Down’s syndrome, Edward’s syndrome and Patau syndrome, cerebral palsy and other types of research to detect the diseases in their early stage.
The Genscreen laboratory is capable of conducting up to a million genetic tests for rare genetic diseases. The laboratory is designed to conduct diagnostic tests to detect various genetic, oncological and clinical diseases in children and adults.
BGI is one of Asia’s leading laboratories that conducts research in genetics, laboratory diagnostics and microbiology.
